

# Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

#### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





## Anti-DPGA anthrax [4C] Bulk Size Ab03882-15.0-BT

This antibody does not have a J-chain and therefore presents as a hexamer, rather than a pentamer.

**Isotype and Format:** Human IgM, Kappa

Clone Number: 4C

**Alternative Name(s) of Target:** DPGA; capsular antigen; γDPGA; gamma DPGA; poly-gamma-d-glutamic

acid; poly-γ-d-glutamic acid; antiphagocytic polypeptide capsule

UniProt Accession Number of Target Protein:
Published Application(s): in vivo, neutralize, ELISA
Published Species Reactivity: Bacillus anthracis

**Immunogen:** The original antibody was generated by immunizing a chimpanzee with fragmented peptides of poly-γ-D-glutamic acid (γDPGA) capsule of B. anthracis conjugated with either B. anthracis recombinant protective antigen (rPA) or tetanus toxoid (TT).

**Specificity:** This antibody specifically binds the poly- $\gamma$ -D-glutamic acid ( $\gamma$ DPGA) capsule of Bacillus anthracis. Bacillus anthracis is surrounded by an antiphagocytic polypeptide capsule composed of poly  $\gamma$ -d-glutamic acid ( $\gamma$ DPGA). The  $\gamma$ DPGA capsule shields the vegetative form of B. anthracis from agglutination by monoclonal antibodies to its cell wall polysaccharide.  $\gamma$ DPGA has been identified recently as a potential target for vaccine development. Bacillus anthracis is a spore-forming bacterium and a causative agent for Anthrax, which is a highly lethal infectious disease in human and poses a great threat as an emerging bioterror agent.

**Application Notes:** The binding characterization of this antibody to  $\gamma DPGA$  of Bacillus anthracis was done using ELISA. The binding affinity of the antibody was measured using surface plasmon resonance. It was reported that the IgG1 version of this antibody binds 10-mer peptide of  $\gamma DPGA$  with a binding affinity of Kd= 0.2 nM. It was reported that a single 30- $\mu$ g dose of this antibody when given to BALB/c mice 18 h before challenge conferred about 50% protection against a lethal intratracheal spore challenge by the virulent B. anthracis Ames strain. When given 8 h or 20 h after challenge, this antibody provided significant protection against lethal infection (PMID: 21187383). This antibody can be used in treatment of infections with antibiotic-resistant strains (PMID: 22069754).

**Antibody First Published in:** Chen et al. Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2): 739–744. PMID:21187383

**Note on publication:** Describes the generation of two antibodies against B. anthracis  $\gamma$ DPGA and evaluates their capacity to protect mice against lethal intratracheal spore challenge.

## **Product Form**

**Size:** 500 µg Purified antibody in bulk size.

**Purification:** Affinity Purified using a recombinant lectin column

Supplied In: PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without

added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C. Concentration: 1 mg/ml. Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.